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Abstract The 5-fluorouracil (5-FU)-based chemotherapy is
a standard treatment for patients with colorectal cancer.
However, a relevant number of patients suffer from severe
toxic side effects, such as haemotoxicity, while lacking
clinical response to adjuvant therapy. The inter-individual
variations of drug toxicity and efficacy of the pyrimidine
antagonist observed in clinical practice are mainly deter-
mined by genetic polymorphisms. The screening of
genotypes, such as thymidylate synthase, dihydropyrimi-
dine dehydrogenase, methylene tetrahydrofolate reductase,
orotate phosphoribosyltransferase or glutathione S-
transferase, could help identifying those patients with
colorectal carcinoma who can actually benefit from a 5-
FU-based therapy. The current chapter elucidates the roles
of the polymorphisms in the enzymes involved in the 5-FU
metabolic pathway as prognostic and predictive markers. It
reports on the relationship between various genotypes in
patients with colorectal carcinoma and their responsiveness
to a 5-FU-based chemotherapy, and concludes with an
outlook on possible future directions in treatment of
colorectal cancer.
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Introduction
Colorectal tumours are a leading cause of cancer death
worldwide. Surgical resection of primary and regional
lymph nodes is among the standard therapies for treatment
of colorectal tumours. Although surgical resection alone is
potentially curative in colorectal cancer patients, many
patients develop local or distant recurrences [1].
In the 1950s, fluoropyrimidines including 5-FU were
introduced into clinical trials. Twenty years ago, adjuvant
treatment of colon cancer patients was validated and
improved the curative rates. Numerous analyses have
shown that 5-FU-based systemic adjuvant chemotherapies
have improved survival in high risk patients. In adjuvant
settings, 5-FU-based chemotherapies are currently an
integral component of the management of colon cancer.
However, its clinical application is limited, because 5-FU has
gastrointestinal and hematological toxicity. The additional
introduction of active drugs, such as oxaliplatin, bevacicu-
mab or cetuximab, has provided clinical benefit for the
patient in both early and late stages of the disease. Adjuvant
therapy for colorectal cancer patients consists primarily of
combinations of 5-FU/leucovorin with oxaliplatin or oral
capecitabine. The combined regimens of 5-FU, leucovorin
and oxaliplatin have been shown to prolong significantly
disease-free survival. In the treatment of colorectal cancer
patients the introduction of the platinum compound oxali-
platin has increased response rates up to 25%, even in
heavily pretreated relapsing patients when administered in
combination with 5-FU [2]. Also, the angiogenesis inhibitor
bevacizumab and the epidermal growth factor receptor
inhibitor cetuximab have shown activities when combined
with 5-FU/leucovorin-based regimens as first-line treatment
of advanced disease. For metastatic disease the 5-FU-based
combination therapy with either irinotecan or oxaliplatin
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plus bevacizumab has resulted in a significant improvement
in response, and disease-free and overall survival. However,
a relevant number of patients still get toxic side effects from
the treatment while lacking a response by the tumour. In the
worst cases, chemotherapy toxicity may accelerate death
[3]. Moreover, the risk of recurrence is still high in many
patients. Therefore, there is a need to tailor the therapy.
Predicting an effective regime with minimal toxicity in the
palliative situation might potentially improve the quality of
care by allowing individualization of treatment. The dose of
agent and the combination of 5-FU with other drugs should
be adapted for patients at high risk.
Even with different doses and schedules, the response rate
of metastatic colorectal cancer is only 21%when treated with
5-FU and leucovorin. To predict the clinical outcome of
colorectal cancer patients treated with adjuvant 5-FU-based
chemotherapy, endeavours have been made to investigate the
efficacy, tolerability and toxicity of 5-FU, together with why
some subgroups do and other groups do not benefit from a 5-
FU-based therapy. Chemotherapy-based toxicity is caused
by many factors such as organ dysfunction and genetic
variability. In particular, polymorphic variations of the
molecules involved in the metabolic pathway of 5-FU may
contribute to the differences in clinical outcome among
patients. Therefore, it is of note to investigate the genotypes
and to generate a pharmacogenetic profile that may help
predicting the clinical outcome of a 5-FU-based chemother-
apeutic regimen. Several types of polymorphisms affect the
gene expression of enzymes in the metabolism of 5-FU and
include insertions, deletions, tandem repeats and single
nucleotide polymorphisms. To choose the effective regime
with minimal toxicity and to limit treatment failure, DNA
derived from different tissues, such as tumour tissues,
leukocytes and blood may be used for the experimental
approaches on the genotypes. Associations between the
potential drug toxicity and the genetic patterns may be
determined by using germ-line DNA. Since the primary
tumour harbours tumour-specific aberrations, which would
otherwise escape analyses, the drug efficacy may be
examined by DNA derived from the primary tumour.
Polymorphisms of thymidylate synthase
As shown in Fig. 1, the action mechanisms of the
fluoropyrimidine 5-FU are the inhibition of thymidylate




















Fig. 1 The 5-fluorouracil (5-FU) metabolism pathway. In tumour cells
5-FU is converted to 5-fluorodeoxyuridine monophosphate (5-FdUMP)
by the action of orotate phosphoribosyltransferase. 5-FdUMP inhibits the
DNA synthesis by competing with deoxyuridine monophosphate
(dUMP) for binding to thymidylate synthase in a complex that is
stabilized by the reduced folate 5,10-methylene tetrahydrofolate. 5-FU
can also inhibit RNA synthesis in a pathway that involves its metabolism
by orotate phosphoribosyltransferase to 5-fluorouridine monophosphate
(5-FUMP) and subsequent conversion to 5-fluorouridine triphosphate (5-
FUTP) via 5-fluorouridine diphosphate (5-FUDP). Extracellular catabo-
lism of 5-FU by dihydropyrimidine dehydrogenase reduces the level of
5-FU for the uptake into the tumour cells
486 EPMA Journal (2010) 1:485–494
synthase (TS) by 5-FdUMP and the metabolic impairment
of RNA by incorporation of 5-FdUTP into RNA [4]. Based
on its polymorphisms and expression levels, TS has been
described to be a predictive factor for the efficacy of the 5-
FU treatment [5, 6]. As a key enzyme it regulates the dTMP
levels by catalyzing the reductive methylation of dUMP by
5,10-methylene tetrahydrofolate. In this rate-limiting reac-
tion, dTMP and dihydrofolate are formed. The thymidylate
biosynthesis is the only de novo source for dTMP which is
a precursor nucleotide for DNA replication. 5-FdUMP, an
active metabolite of 5-FU binds to TS, and causes the
formation of a stable ternary complex which suppresses the
enzyme activity of TS [7]. As a result, dUMP molecules
accumulate along with a decrease in dTMP levels. After
conversion of dUMP into dUTP, dUTP replaces dTTP as a
substrate for DNA polymerases and is incorporated into the
newly synthesized DNA strand. Uracyl-N-glycosylase
actually detects incorrectly incorporated uracil bases in the
DNA strand, e.g. after the spontaneous deamination of
deoxycytidine. Although it removes the incorporated uracil
bases, the new DNA strand is incorrectly repaired by dUTP
or 5-FdUTP, because dTTP is not available.
Since TS is required for the delivery of nucleotides used
in DNA replication, and consequently, for tumour cell
proliferation and tumour growth, numerous reports have
engaged in studying the polymorphisms of TS gene, and
demonstrated that the intratumoural yields of TS mRNA
transcripts and protein molecules may be a predictor of
response and survival to 5-FU-based chemotherapy [8–10].
Whereas low TS mRNA levels may associate with a better
response to 5-FU-based chemotherapy and improve 5-year
survival, higher expression levels may fail to respond to
this treatment [11, 12]. However, the minor TS levels may
also enhance the cytotoxic side effects of 5-FU provoking
the determination of patient therapy [9, 13]. These
observations suggested that screening of TS genotype that
is linked with TS expression might have the potential to
identify those patients with colorectal carcinoma who
benefit from a 5-FU-based adjuvant therapy. So far, three
functional polymorphisms of the TS gene have been
identified: variable number tandem repeat (VNTR), single
nucleotide (SNP) and deletion (1494del6) polymorphisms,
which significantly affect TS gene expression.
With respect to the VNTR polymorphism, the 5´
regulatory region of the TS promoter contains a variable
number of a 28-bp repeat (R), mainly, double (2R) or triple
(3R) repeats. These tandem repeats contain E-boxes for the
transcription factor USF-1 (upstream stimulatory factor-1)
that activate transcription of the TS gene by binding to
these motifs [14]. Accordingly, the higher number of
repeats is associated with a higher promoter activation and
transcription. It was reported that of the three VNTR
groups, including 2R/loss, 2R/3R and loss/3R, the poly-
morphism 2R/loss exhibited the lowest mRNA expression
level, the best response to 5-FU and the longest medium
survival time [15].
A further polymorphism is a G/C (guanine/cytosine)
substitution of the 12th nucleotide in the second repeat of
the triple repeat variant (3RC/3RG). The presence of the SNP
in the USF-1 binding site causes a decrease in transcriptional
activity of the wild type triple repeat (3RG/3RG) variant
which is comparable with the 2R/3RG variant [16].
Functional analysis showed that a plasmid construct encod-
ing for the 3RG/3RG variant had 3–4 times higher
translation efficiency than other polymorphic sequences [17].
In addition, a 6-bp deletion (1494del6) polymorphism
was identified in the 3´ untranslated transcriptional region
(3´UTR) of the TS gene. An association between this
deletion (del) and the mRNA instability has been described
[18]. To investigate the function of the 1494del6 polymor-
phism in vitro, a luciferase system was used, and showed a
∼70% decrease in luciferase activity and mRNA levels. The
TS 3′UTR construct containing the heterozygous del/6 bp
deletion also had a higher rate of mRNA degradation
compared to the wild type (6 bp/6 bp) construct [18]. As
examined in studies by Kawakami et al. [19] and Uchida et
al. [20], the deletion at the TS locus in tumour cells may
affect the actual expression level. It seems that TS promoter
and 3´UTR polymorphisms are dependent on one another,
because disequilibrium between both polymorphisms may
be a general feature of the TS gene [21, 22]. Conversely,
Merkelbach-Bruse et al. disproved an association between
microsatellite instability (MSI) status and TS expression.
Based on a higher mRNA stability, they observed that the
3R/3R or 2R/3R genotypes of TS had higher mRNA levels
whereas polymorphic variants of the 3′UTR did not
influence the TS mRNA level [23].
The TS gene is localized on the short chromosomal arm
18. Vogelstein et al. reported that ∼40% of patients with
colorectal tumours had deletions in this region [24]. Other
laboratories even found losses of heterozygosity (LOH) in
more than half of the examined carcinomas [25]. These
patients possess an imbalance of the TS allele that remains
occult on examining exclusively the genotype of the
leukocyte (wild type) DNA. Frequent LOH at the TS locus
was detected in 62% of the informative cases by RT-PCR
using TS mRNA and microsatellite analyses of the marker
D18S59 located downstream of the TS gene sequence [19].
These high frequencies of DNA losses support an unstable
TS genotype during carcinogenesis. It is of note that in
respect of the repeat number of the heterozygous genotype
(3R/2R) bearing LOH, the cancer tissue with the genotype
2R/loss expressed a significantly lower level of TS protein
than did the tumour with the genotype 3R/loss [19]. These
data indicate a significant difference between the TS
genotypes of tumour and normal tissues.
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In respect to the different TS variants, discrepancies in
risk of toxicity, clinical outcome and gene expression have
been reported, because most studies have considered only a
single TS polymorphism, [16]. Moreover, it should be
critically noted that genotyping of the TS variants in
numerous analyses was performed by using normal
leukocyte DNA instead of tumour DNA indicating that
the occurrence of LOH was not considered [26]. A recent
study explored the effect of the three polymorphisms of the
TS gene on overall and progression-free survival of
colorectal cancer patients subjected to 5-FU-based chemo-
therapy and showed that the 3RG/3RG 6 bp/6 bp combined
genotype (wild type, high expression) identified a subgroup
of advanced patients with poor prognosis. However, none
of the studied polymorphisms alone affected overall or
progression-free survival [27]. A further study investigated
the three polymorphisms of the TS gene and the response to
a 5-FU-based chemotherapy in patients with colorectal
cancer and liver metastases. The distinction between high
(2R/3G, 3RC/3RG and 3RG/3RG) and low (2R/2R, 2R/
3RC and 3RC/3RC) TS expression genotypes referred to a
significant association with tumour response [28]. Tumour
recurrence is a major problem after curative resection in the
management of colon cancer therapy. Lurje et al. showed
that high-expression variants of TS may help to identify
stage II and stage III colon cancer patients who are at high
risk of developing tumour recurrence, and also those who
are more likely to benefit from a 5-FU-based adjuvant
chemotherapy. Patients harbouring the TS 3RG 6 bp
haplotype were at highest risk in developing tumour
recurrence. In both univariate and multivariable analyses,
TS 3RG alone or in combination with TS 1494del6 proved
to be adverse prognostic markers [29].
Numerous reports have not only argued for, but also
against, the incidence of diverse polymorphisms occurring
with a better clinical response and overall survival of the
patients [9, 30–32]. A recently published research showed
that the different polymorphisms of the TS gene (SNP and
VNTR) may not be related with disease-free survival in
patients with stage III colorectal cancer receiving adjuvant
chemotherapy [33]. In our study, we investigated whether
the presence of single polymorphisms (VNTR, 1494del6
and SNP), LOH at the microsatellite markers D18S59,
D18S1140 and D18S976 mapped up- and downstream to
the TS locus, and combinations of them at the TS locus in
leukocytes, primary tumour and blood of patients with
advanced colorectal carcinoma who received 5-FU-based
chemotherapy, as well as their increased DNA concen-
trations in blood, were associated with the clinical and
histopathological risk parameters of these patients. Apart
from the significant correlations of the cell-free serum DNA
concentrations with the 1494del6 and combined polymor-
phisms, and of the age with VNTR and VNTR plus
1494del6, the combined polymorphisms detected in blood
serum only tended to associate with the response to therapy by
the patients. Moreover, the borderline significance detected in
serum showed rather an inverse correlation to the number of
polymorphisms and a low impact on response to 5-FU. Our
findings provided an insight into the molecular diversity of
the regulation of TS gene expression, and suggested that the
variance in responses to 5-FU-based chemotherapy cannot
consistently be explained by the genetic alterations detected in
the TS gene [34]. Although numerous in vivo and in vitro
studies have described the association between TS genotype
with TS protein level [9, 14, 17], a recent report could not
find such correlations by immunohistochemistry. This
laboratory also showed that the immunohistochemistry data
did not significantly associate with the clinical outcome of
patients, and that VNTR was the only polymorphism of the
TS gene demonstrating a significant association with later
recurrence and cancer-specific survival. Assessment of the
two other polymorphisms (SNP and 1494del6) did not
deliver any additionally prognostic information [35].
Summing up, these studies show that the prognostic
value of TS genotypes in patients receiving adjuvant 5-FU-
based chemotherapy is still a matter of controversy. They
also reflect the complexity of TS gene regulation and that
other enzymes involved in thymidylate biosynthesis should
also be considered.
Polymorphisms of orotate phosphoribosyltransferase
As shown in Fig. 1, 5-FU is preferentially phosphorylated
by the orotate phosphoribosyltransferase (OPRT) to produce
the nucleotide 5-FdUMP. 5-FdUMP is then phosphorylated
to 5-FdUDP, which can be either reconverted to 5-FdUMP or
phosphorylated to the active nucleotide 5-FdUTP. Now, 5-
FdUTP can be extensively incorporated into RNA (F-RNA),
disrupting normal RNA process and function [36]. An
inhibitor of OPRT is potassium oxonate which could lower
the levels of 5-FdUMP leading to a decrease of ∼70% in F-
RNA synthesis in the small intestine and a reduction in
gastrointestinal toxicity [37].
In mucosal carcinoma and infiltrative lesions the expres-
sion of OPRT correlated significantly with the presence of
lymphovascular invasion suggesting that OPRT is involved in
the invasion and metastasis of colorectal tumours [38]. On the
other hand, using immunohistochemistry, Tokunaga et al.
found that a high OPRT expression in stages II–IV disease
was correlated with a better overall survival [39]. Common
polymorphisms, including SNPs 213G/C (guanine/cytosine
substitution at position 213), 638G/C, 1050T/A (thymine/
adenine) and 1336A/G (adenine/guanine), have been identi-
fied in the coding region of OPRT [40]. The SNP 213G/C of
OPRT may be a significant predictor of 5-FU-induced
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toxicity in patients treated with 5-FU adjuvant therapy, and
have an independent value for prediction of severe grade 3 to
4 diarrhea [41]. In contrast, the SNPs 638G/C, 1050T/A, and
1336A/G of OPRT may have no major influence on 5-FU
sensitivity [42].
Polymorphisms of dihydropyrimidine dehydrogenase
The systemic exposure to 5-FU is fundamentally determined
by the genetically polymorphic enzyme dihydropyrimidine
dehydrogenase (DPD). DPD is the initial and rate-limiting
enzyme in the three-step catabolic pathway of 5-FU (Fig. 1).
More than 80% of administered 5-FU is degraded by DPD
in human liver. Deficiency in the DPD enzyme activity
caused a delay in the clearance of 5-FU from blood and the
accumulation of 5-FU [43]. As a result, chemotherapeutic
toxicity of 5-FU has been associated to low levels of DPD
enzyme activity. At least 50% of patients who had highly
toxic side effects were genotypically heterozygous or
homozygous for SNPs in the DPD gene [44, 45].
As determined by immunohistochemistry and/or RT-
PCR, analyses on DPD expression in primary colorectal
tumours of patients treated with 5-FU-based chemotherapy
showed either significant associations of a low DPD
expression with prolonged overall and disease-free survival
[46, 47] or no associations [48]. Accordingly, immunohis-
tochemistry of paraffin-embedded primary tumour tissues
demonstrated that patients with high DPD expression levels
had significantly shorter disease-free and overall survival
than patients with low DPD levels. In combined analyses,
including the determination of TS and DPD expression,
patients with low TS and DPD had the best outcome in terms
of disease-free and overall survival. This retrospective study
suggested that the combined assessment of TS and DPD
might be useful in evaluating the prognosis of patients with
Dukes’ B and C colon carcinoma receiving 5-FU adjuvant
chemotherapy [46]. However, conflicting results have been
reported in metastatic patients [39, 49, 50].
Although the precise role of DPD as a prognostic factor
in the efficacy of 5-FU still has to be established, there is
evidence that patients with a DPD deficiency are prone to
the development of severe 5-FU-associated toxicity. The
exon 14-skipping mutation (IVS14+1G/A mutation) pro-
vokes a changed splice site leading to an aberrant protein
sequence and a loss of the catalytic activity of DPD. This
gene variant accounted for 24–28% of all patients suffering
from severe 5-FU toxicity [51]. In the cofactor binding
domain and the electron transport domain of DPD the
2846A/T polymorphism leads to an amino acid substitution
and a reduced enzyme activity. This gene variant has been
detected in 2% of the population [52]. To tailor 5-FU
administration and determine strategy in first-line chemo-
therapy of advanced colorectal cancer, Capitain et al.
investigated the polymorphisms of DPD and their influence
on tolerance and toxicity in patients initially treated with 5-
FU. They detected that the toxicity was significantly linked
to the SNP 2846A/T and the splicing mutation IVS14+1G/
A of DPD [53]. In five out of eight cases with severe side
effects, Amstutz et al. observed that a potential association
existed between a haplotype containing three intronic poly-
morphisms (IVS5+18G/A, IVS6+139G/A and IVS9+51 T/G)
and a SNP (1236G/A). Comparing their data with those from
other studies, they suggested that the relative importance of
particular DPD mutations (IVS14+1G/A and 2846A/T) for
predicting severe 5-FU toxicity differs geographically across
Europe [54]. Moreover, numerous further polymorphisms in
the DPD gene, such as 85T/C, 496A/G, 1601G/A and
1627A/G, have been identified but their effect on transcrip-
tion and their influence on clinical outcome of colorectal
cancer patients treated with 5-FU are still unclear [55].
Polymorphisms of methylene tetrahydrofolate reductase
5,10-methylene tetrahydrofolate reductase (MTHFR) is a
key enzyme in the regulation of intracellular folate levels. It
affects both, DNA synthesis and methylation. In a one-
carbon metabolism it catalyses the irreversible conversion
of 5,10-methylene tetrahydrofolate to 5-methyl tetrahydro-
folate to generate the folate derivative for homocysteine
remethylation to methionine (Fig. 1). In human cancer cells
the inhibition by specific antisense RNA molecules against
MTHFR affected tumour growth, and 5-FU could potenti-
ate this significant inhibitory effect [56].
Two common SNPs (677C/T and 1298A/C) have been
described to reduce MTHFR enzyme activity and contrib-
ute to an alteration of intracellular folate distribution. The
677C/T transition in exon 4 results in an alanine to valine
substitution in the predicted catalytic domain of MTHFR.
This substitution made the enzyme thermolabile, and
reduced ∼70% and ∼35% of its enzyme activity in
homozygotes and heterozygotes, respectively [57]. The
1298A/C transition in exon 7 results in a glutamate to
alanine substitution within the regulatory domain of the
protein and led to a decreased enzyme activity, albeit not to
the same extent as that of the 677C/T allele [58]. Since a
decrease in MTHFR enzymatic activity may lead to a
decrease in intracellular 5-methyl tetrahydrofolate concen-
trations, it is presumed that tumours exhibiting the rare
MTHFR variants may be more sensitive to 5-FU cytotox-
icity than patients with a wild-type genotype. Moreover, the
concomitantly higher concentrations of 5,10-methylene
tetrahydrofolate may in turn favour the formation and
stability of the inhibitory ternary complex consisting of TS,
5,10-methylene tetrahydrofolate and 5-FdUMP.
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Several clinical studies have investigated the potential
predictive role of these genetic variants in toxicity and
efficacy of 5-FU, but contradictory data have been
published [59]. Fernandez-Peralta et al. examined the
relationship of 677C/T and 1298A/C polymorphisms with
biological, clinicopathological, genetic and epigenetic fea-
tures of the colorectal tumours and showed that both
polymorphisms were relevant and independent factors of
patient outcome after 5-FU-based treatment. The variant
677C/T had a protective effect on colorectal cancer
development, whereas the variant 1298A/C did not produce
any effect on disease risk [60]. Moreover, both poly-
morphisms were reported to be associated with a sex-
specific clinical outcome in metastatic colon cancer patients
treated with FU-based chemotherapy. The 1298A/C poly-
morphism in MTHFR correlated statistically significantly
with the overall survival of female patients with metastatic
colon cancer, but no such correlation was observed for male
patients. Therefore, it was suggested that this variant might
be a prognostic marker for female patients with metastatic
colon cancer [61]. These findings have been supported by
another study showing that the overall survival was higher
for C/C female patients than for A/C female patients [62].
Etienne et al. evaluated the MTHFR polymorphisms in
patients with metastatic colorectal cancer who were treated
with 5-FU and leucovorin. Their response rate was
significantly associated with the 677C/T genotype, but not
connected with the 1298A/C genotype [63]. In the study by
Jakobsen et al. the response rate was 66% for 677T/T
compared with 33% and 21% for 677C/C and 677C/T,
respectively. No correlation was observed in the case of
1298A/C polymorphism [64]. In contrast, the 677C/T
polymorphism was not associated with the clinical response
of metastatic colorectal cancer patients who received 5-FU/
oxaliplatin/leucovorin chemotherapy and caused severe
grade 3 to 4 diarrhoea [65]. Although the variant 677C/T
did not affect the risk of colorectal cancer, it affected the
sensitivity to chemotherapy and the risk of side-effects and
therefore survival in stage III and possibly stage IV colon
cancer [66]. It was also reported that patients initially
treated with 5-FU had a severe toxicity when they were
homozygous carriers of 1298C/C [67].
As pointed by out several studies [68–70] and docu-
mented by the above-described data, SNPs in the MTHFR
gene cannot be considered as independent factors of outcome
in colorectal cancer patients treated with 5-FU-based
chemotherapy.
Polymorphisms of glutathione S-transferase
Glutathione S-transferases (GSTs) are members of a
superfamily of dimeric phase II detoxifying enzymes. They
protect cellular macromolecules from damage by catalyzing
the conjugation of toxic and carcinogenic electrophilic
molecules with glutathione. The resulting complex is less
toxic and more readily excreted. In contrast to the other
members of the family, such as GSTT1, GSTM1 and
GSTA1, the variant GSTP1 is predominantly expressed
in colon. Diverse common SNPs have been described for
the GST genes that either abolish or decrease or increase
the enzyme activity of GSTs for electrophilic substances
[67].
To predict the toxicity in metastatic colorectal cancer
patients treated with 5-FU/irinotecan/leucovorin regimens,
the roles of 69C/T in GSTA1, 105Ile/Val (isoleucine/valine
substitution) in GSTP1, and null allele (homozygous DNA
deletion) in GSTT1 and GSTM1 were evaluated. In human
tissues a decline in GSTP1 activity was reported to parallel
with an increasing number of 105Ile/Val alleles in GSTP1
[71]. Thus, a valine residue at position 105 of the GSTP1
protein resulted in decreased enzyme activity. A strongly
significant association was observed between the null allele
in GSTT1 and gastrointestinal toxicity. In comparison to
23% of patients with an intact GSTT1 genotype, 57% of
null allele carriers developed gastrointestinal grade 3
toxicity. Thus, patients with a null allele in GSTT1 had a
greater probability of developing toxicity to 5-FU/irinotecan/
leucovorin than patients who lacked this deletion. These
findings indicated that the null allele in GSTT1 gene might
be considered as a new marker when the treatment schedule
is administered to metastatic colorectal cancer patients.
Besides, the other polymorphisms analysed in that study
did not refer to toxicity [72]. In addition, the neurotoxicity of
patients with advanced colorectal cancer treated with a
chemotherapy of 5-FU, oxaliplatin and folinic acid was
reported to be significantly associated with the 105Ile/Val
polymorphism inGSTP1. Carriers of the 105Val/Val genotype
were more prone to suffer from grade 3 neurotoxicity than
carriers of 105Ile/Val and 105Ile/Ile genotypes [67].
To predict the clinical outcome of 5-FU/oxaliplatin-
based chemotherapy in patients with advanced colorectal
cancer and refractory stage IV disease, the SNP 105Ile/Val
in GSTP1 was examined. Stoehlmacher et al. demonstrated
that the 105Ile/Val variant might be a predictor for time to
progression to 5-FU/oxaliplatin, as well as overall survival.
They suggested that patients with this variant allele may
experience protracted detoxification of oxaliplatin, and that
a prolonged exposure of the tumour to oxaliplatin may lead
to an increased overall efficacy of the drug and a superior
survival of the patients. In contrast, the null alleles of
GSTT1 and the GSTM1 linked to an abolished enzyme
activity had no effect on clinical outcome [73]. Moreover,
the same laboratory showed that the 105Ile/Val polymor-
phism in GSTP1 was associated in a dose-dependent
fashion with increased survival of patients with advanced
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colorectal cancer receiving 5-FU/oxaliplatin chemotherapy.
Patients with the genotypes 105Val/Val, 105Ile/Ile and
105Ile/Val had a median survival of 24.9, 7.9 and
13.3 months, respectively [74].
Although the published data are contradictory, they
underline the fact that GST genotyping of individual
colorectal cancer patients receiving 5-FU-based chemother-
apy may contribute to improved therapy planning.
Interactions between the different genotypes
Some studies tried to go beyond the analyses of single
genetic polymorphisms to a more comprehensive investi-
gation that identifies genomic variants and patterns of
several polymorphisms. However, also these investigations
showed contradictory data, thus leading to increasing
uncertainty in the identification of reliable predictive
genetic markers of drug response. The interactions between
ten candidate polymorphisms of nine genes and the
incremental toxicity of adding irinotecan or oxaliplatin to
FU were investigated in a large randomized trial. Among
the different putative pharmacogenetic markers assessed,
the polymorphisms of TS, DPD, MTHFR and GSTP1 were
also analyzed. However, none of the polymorphisms was
significantly associated with the toxicity of any regimen
and the primary outcome [75]. Moreover, six gene poly-
morphisms, among others of GSTP1, MTHFR and TS,
were assessed in Taiwanese patients who were diagnosed at
high-risk stages and administered adjuvant chemotherapy
regimens that included 5-FU and leucovorin. Also in this
study, no correlations between genetic polymorphisms and
clinicopathological features of the patients were detected
[76]. However, Capitain et al. who investigated different
germinal polymorphisms and 5-FU plasma clearance in
patients of advanced colorectal cancer initially treated by 5-
FU reported that the overall survival of the patients with a
3R/3R genotype of TS associated with the homozygosity of
C/C for 677C/T or A/A for 1298A/C of MTHFR was
statistically shorter [53].
These data show that there is a considerable need to
increase efforts in the screening of several polymorphic
variants in the 5-FU metabolic pathway to improve clinical
outcome in the treatment of colorectal cancer,
Conclusions
The pharmacogenetics of drug-metabolizing systems deals
with the identification of genetic polymorphisms that are
responsible for inter-individual variation in the response to
drug therapy. In the current chapter, pharmacogenetic
studies investigating the drug targets of the 5-FU metabo-
lism pathway in the treatment of colorectal cancers have
been discussed. Several enzymes are involved in the
catabolism and anabolism of 5-FU, and their activity varies
largely between individuals. As a result the anti-tumour
activity of 5-FU is limited by the genetic polymorphisms of
these enzymes.
Inconsistent data on the relationship of the diverse
variants of the thymidylate synthase, dihydropyrimidine
dehydrogenase, methylene tetrahydrofolate reductase, oro-
tate phosphoribosyltransferase and glutathione S-transferase
to a better clinical outcome and survival of the patients, and
to response to drug toxicity have been published. To date,
this discrepancy underscores the complexity of the 5-FU
metabolic pathway. Since several enzymes with diverse
polymorphisms are involved in this pathway, it is question-
able to only examine the polymorphisms of one enzyme
and to ignore the impact of the genotypes of the other
enzymes on the clinical outcome of the patients. In
addition, the contradictory data amongst the various studies
may be due to retrospective analyses and relatively small
patient cohorts. Further reasons may be the performance of
different techniques, such as immunohistochemistry and
RT-PCR, which have been used to examine the expression
of these enzymes, the genotyping in normal or tumour
tissues, missing PCR-based microsatellite analyses for the
evaluation of LOH, variable doses and schedules of 5-FU-
based chemotherapy and variable tumour stages of the
patients.
To enhance therapeutic effect and to minimize toxicity of
5-FU-based chemotherapies, it is important to gain a better
understanding of the metabolism of 5-FU agents and to
scrutinize which molecular determinants exert a dominating
influence on the response to 5-FU. To advance 5-FU-based
chemotherapies, multivariable approaches on diverse mo-
lecular markers and prospective clinical trials with large
patient cohorts displaying statistical power are required.
The identification of relevant germ-line polymorphisms as
well as tumour-specific somatic mutations, combined with
their mRNA or protein expression levels in tumour tissue,
might permit more effective and individualised 5-FU-based
chemotherapy in future. Selective genotypical and pheno-
typical information should facilitate the performance of
individualised chemotherapy regimen and combinations of
chemotherapeutic agents with the adequate doses of drugs.
Technologies, such as microarray and proteomics, may lead
to the identification of predictive markers and should
improve the further development of patient treatment.
Finally, for improving the outlook of patients with
colorectal cancer, a number of new agents (e.g., capecita-
bine eniluracil, tomudex) targeted to the enzymes in 5-FU
pathway have been synthesized, and novel combinations of
5-FU or its analogs with agents (e.g., oxaliplatin, irinotecan)
have been examined.
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